Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462383 · ClinicalTrials.gov registry record
The Role of the EKG in Anticancer Drug Development
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 525
- Enrollment target
NCT01462383: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT01462383 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 525 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01462383 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 525 participants
- Enrollment target
Study Summary
Primary Objective: -Evaluate incidence of cardiac complications in Phase I patients. Secondary Objective: -To identify variables (i.e. number of electrocardiograms (EKG) performed) that lead to the detection of cardiac events.
Primary Outcome
Data review of studies, active between January 1, 2006 and December 31, 2009, who included ECGs in their safety evaluations. Use of identification and descriptive analysis of cardiac events occurrence in the phase I population to define role of protocol required EKGs in their detection. Statistical analysis performed in a descriptive fashion with paired and multivariable analyses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-11 |
What the finished NCT01462383 record still lists
NCT01462383 is an observational study that tracks outcomes without assigning an intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01462383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01462383 about?
NCT01462383 is a clinical study titled "The Role of the EKG in Anticancer Drug Development". Primary Objective: -Evaluate incidence of cardiac complications in Phase I patients. Secondary Objective: -To identify variables (i.e. number of electrocardiograms (EKG) performed) that lead to the detection of cardiac events.
What is the current status of trial NCT01462383?
This trial is currently completed. The enrollment target is 525 participants. The study started on 2011-01. Estimated completion is 2011-11.
Who is sponsoring clinical trial NCT01462383?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia